posted
Post your hot plays for wendsday and your reasoning behind it. Please don't just post the symbol with no reasoning just because you own shares....I hate that crap =)
My pick is ETIM and I'm sure most of you know why. This pinky is getting all kinds of attention and media coverage, and BIG news is expected tommorrow, most likely before the market opens. Had a nice run last Thursday, gapped and then settled on Friday and has moved nicely so far this week. I strongly believe tommorrow will be the breakout day!
IP: Logged |
posted
IDWD - ($1.12) - Announcement pre-opening re: details of $2.35 buyout...if it's solid news it will fly, if there is any postponement of the buyout it will drop below $1. There's alot of chatter about the integrity of IDWD, but I've already flipped it for good gains. Ride the news!!
IP: Logged |
AVVAA World Health Care Products CEO Issues Letter to Shareholders
LUMBY, British Columbia, Oct. 24 /PRNewswire-FirstCall/ -- AVVAA World Health Care Products, Inc. (OTC Bulletin Board: AVVW), a biotech company offering global customers therapeutic skin and health care products, issued the following letter to its shareholders:
Dear Valued Shareholders:
With the end of calendar year 2006 just around the corner, avVaa World Health Care Products has implemented a number of directives that will impact our future growth plans and operating strategies as we move forward with full commercialization of our human and animal care product lines.
As an emerging growth company operating in a competitive industry such as ours, sufficient funding is crucial to the continued development and long-term success of our business model. Toward that end, avVaa recently secured a $2 million private placement funding, the proceeds of which are being used to further the Company's operating strategy and general corporate development purposes. The funding is in the form of convertible notes, at a 6% interest rate, which are convertible into common shares at a discount computed on a formula basis. As part of this financing transaction, the Company granted the investors 36 million share purchase warrants exercisable at a price of $0.16 per share. The details of the financing transaction are contained in the Company's financial statements available at http://www.sec.gov.
In recent months, avVaa has also added a number of new advisors to our Board of Directors to ensure continued leading-edge support for the completion of the Company's strategic business plan.
New advisor Dr. Mario Zamora, a well-respected healthcare specialist, has been studying the benefits of our NeuroSkin line of human skincare products for industry publication and presentation. Dr. Zamora recently instituted a Pilot Program in Houston, Texas, in conjunction with the Hispanic Health Institute, leading a sales and marketing campaign to secure additional sales for avVaa products, through advertising on major Spanish television and radio outlets for a period of six weeks. During that time, Dr. Zamora and avVaa's sales agents expect to explore direct sales potential for our products in Hispanic markets, as well as seek additional distributorships to introduce our products to this highly coveted market segment. Success in Houston will allow us to extend the program nationwide over the next several quarters. Product sales in conjunction with this campaign are expected to be forthcoming.
A veterinary specialist in dermatology and new advisor to the Board, Dr. Gene Nesbitt, has been working with management for some time in order to ensure avVaa's pet and equine care products are of the highest quality and effective for successful introduction to the growing pet and animal care products market throughout North America. Dr. Nesbitt has completed a number of studies on the benefits of our all-natural pet and equine care products and will be presenting his papers at a number of trade shows, veterinarian conventions and other planned industry events in the coming year.
While avVaa's board has grown in recent months, so have sales and marketing campaigns for both the Company's human and animal care product lines. Recent collaboration with AdSouth Partners, Inc. resulted in full-page print advertising placement in magazines nationwide with substantial readerships in our target market segments. A full-color brochure has also been completed for additional planned promotional activities. Our dedicated Customer Sales and Service Agents continue to support the strength of recent campaigns by filling orders as they arrive and maintaining customer relationships to facilitate continued sales and reorders.
Additional sales and marketing efforts planned in the coming weeks include test-marketing programs in targeted chain and independent stores in California and the Northwestern U.S. to ensure successful supply chain management and customer services are in place to handle large, upcoming projected sales. Upon pilot testing completion, expected within the next 60 days, chain and independent stores throughout the Northwest are expected to begin stocking NeuroSkin products for their customers.
In our primary healthcare products and services market, industry trade show events are an important part of successful market introduction for new products. Accordingly, we will attend a number of events to promote our products and present study findings to the industry's finest throughout North America this year, including attendance at the prestigious American Academy of Dermatology's 65th Annual Meeting in Washington D.C. this coming February.
In addition to our human healthcare products, we have also been working closely with bulk pet products suppliers to sell our products and are currently negotiating a possible 2007 re-branding (private labeling) of our Animal Care Products through a large, global pet products supplier. On the heels of recent successes in this marketplace, we will attend the most well respected animal and pet care products industry trade shows throughout the coming year.
In conjunction with trade show attendance and sales and marketing efforts, we are now sponsoring many local, regional and national pet and equine events throughout Canada and the U.S. These sponsorship programs have been an excellent resource to ensure product placement in the hands of our target consumers and allow us to promote our products at minimal costs. Additionally, a graphic artist has been retained to ensure colorful graphic designs for our entire line of animal and human products.
Finally, at our annual meeting this past July, the Board approved the appointment of a new auditing firm Davidson & Company LLP and the formation of an Audit Committee. As a result, avVaa's financial reporting process is now strengthened, as the Audit Committee, comprising two independent directors, reviews and approves annual and quarterly financial statements and regulatory filings. New auditors Davidson & Company LLP, the Company's accounting advisors Lancaster & David, Chartered Accountants, the Audit Committee and management have worked closely together to streamline the reporting process. As a result, for the first time in two years the Company has met its filing deadlines for quarterly reporting to the SEC.
Moving toward another year at avVaa, management remains committed to building value for its shareholders over the long-term and maintaining open communication along the way. We are excited about the positive consumer and retail responses to our products we have seen this year, for both human and animal care lines throughout North America, and will continue to concentrate our efforts on successful product placement and strategic sales and marketing.
We look forward to additional operational and product improvements to the benefit of our customers and shareholders in the coming months and pledge to continue Improving Quality of Life -- Naturally!
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Razz]](tongue.gif)
![[Wink]](wink.gif)
